Concepedia

Corina Dota

CD

8

Publications

340

Citations

8

H-Index

2002

Active since

Affiliations

AstraZeneca (Sweden)(Current)

AstraZeneca (United Kingdom)

Center for Drug Evaluation and Research

Astellas Pharma (United States)

United States Food and Drug Administration

Corina Dota is an author at AstraZeneca (Sweden) specializing in pharmacotherapy, medicine, and cancer therapeutics.

Top concepts

Publications per year

2002–2022

8

Publications

8

Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

Börje Darpö, Charles Benson, Corina Dota et al. · Clinical Pharmacology & Therapeutics · 2015 · 176 citations · Full text

An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data

Christopher E. Pollard, Matthew Skinner, Stanley E. Lazic et al. · Toxicological Sciences · 2017 · 55 citations · Full text

, , +15

Computer‐Based Analysis of Dynamic QT Changes: <i>Toward High Precision and Individual Rate Correction</i>

Corina Dota, Bo Skallefell, Nils Edvardsson et al. · Annals of Noninvasive Electrocardiology · 2002 · 24 citations · Full text

Can Bias Evaluation Provide Protection Against False‐Negative Results in QT Studies Without a Positive Control Using Exposure‐Response Analysis?

Georg Ferber, Meijian Zhou, Corina Dota et al. · The Journal of Clinical Pharmacology · 2016 · 23 citations

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies

Helen Swaisland, Ruth Plummer, Karen So et al. · Cancer Chemotherapy and Pharmacology · 2016 · 17 citations

, , +6

Rows per page

1–5 of 8